News
Coming soon
This is Cogience, a brand new site by Mark Goodlad that's just getting started. Things will be up and running here shortly, but
25+
Years in market access & health economics
25+
Years of project management & technology delivery
50+
Global engagements led by senior experts
3
Sectors — pharma, biotech, medical devices
Global
Payer advisory network across key HTA markets
What we do
Transforming Complex Science
into Market Access Outcomes
We work across the full market access and evidence lifecycle — from early asset strategy through to reimbursement and launch.
Strategy & Market Access
Global and regional market access strategy, pricing and launch sequencing, competitive landscape, payer research, and due diligence. Includes international reference pricing (IRP) simulation and optimised launch sequencing to protect price corridors across markets.
Health Economics & Evidence
Systematic literature reviews and network meta-analyses, individual-patient-data and single-arm trial analysis, survival-curve extraction, cost-effectiveness and budget-impact models, and real-world evidence strategy. Built to withstand HTA scrutiny — including PICO alignment ahead of submission and EU JCA-ready data packages.
HTA & Reimbursement
HTA landscape assessments, submission strategy and dossier development, payer engagement and advisory boards, reimbursement negotiation support. Fluent in the regulatory–HTA "double gate" — ensuring data generated for FDA/EMA also satisfies payer value requirements, including the EU Joint Clinical Assessment (JCA).
Value Communication
Global Value Dossiers, value proposition development, payer communication materials, and scientific publications strategy. Moving beyond static documents toward evidence packages that can be updated as new real-world data emerges.
Project & Delivery Management
End-to-end project management, cross-functional workshop facilitation, and training. On time, on scope, on budget.
AI Enablement
We build the AI workflows your access team will actually run — literature triage, evidence pipelines, dossier drafting, payer-decision simulation — and hand them over with the governance, validation, and training to use them safely. Outputs your committee will defend.
The new operating reality
Faster decisions. Leaner teams.
Zero margin for error.
Healthcare access has compressed. HTA windows tighten, EU JCA is rewriting submission economics, and lean teams are expected to ship enterprise-scale evidence. AI isn't a feature anymore — it's the operating layer.
Speed
Approval and reimbursement timelines have compressed from months to weeks. AI-accelerated modelling and automated evidence pipelines move at the pace your market demands.
Efficiency
Senior teams, not large ones. Reusable value architectures and AI-augmented analysis let a lean group deliver what used to take a department.
Accuracy
One mis-coded comparator sinks a submission. AI-enabled validation, version control, and PICO alignment layered over every deliverable — what you submit is what you meant.
Purpose-built platform
Cogience.Advise — payer insight at global scale,
without the schedule conflicts.
Cogience.Advise is our virtual advisory board: an async-first engagement platform that convenes 5–10 senior payers, HTA evaluators, KOLs, and patient advocates over two to three weeks. Built for indications where in-person advisory is impractical — orphan drugs, multi-market launches, time-pressured strategy work.
- Senior moderation throughout — no junior layer
- HTA template library: NICE HST, CADTH, HAS, AMNOG, LSDP, Sakigake, US payer archetypes
- AI-assisted analysis — every output validated by a qualified expert
- Executive summary in 72 hours, full report in two weeks
Insights
Research & thinking
"As a full-time consultant working with my Market Access team, Farzana impressed me with both her industry knowledge and technical pricing expertise."
Get in touch
Let's talk about your project.
Tell us about the asset, the question, and the markets in scope. We'll come back to you within a working day.
Book a 30-minute call